Tonix Pharmaceuticals Holding Corp.: updates and filings

TNXPNASDAQHealthcare · Pharmaceutical Preparations

Price

$2.38

November 20, 2026Market cap $46M

What Ploutos Investor adds for Tonix Pharmaceuticals

Part of Ploutos Investor, €9.99 a month

See the plans
  • The full history: 3 fiscal years, from 2023
  • The estimated fair value, with its range and its certainty
  • The full analysis, 18 a month
  • More questions to the chat on its filings
  • Excel with every year
  • An email when it reports, changes its dividend or an officer buys

Sign in with a free account to see the last 5 fiscal years.

Notes on these figures

  • The share price has fallen 47% since Nov 9, 2026, when the 10-Q these figures come from was filed ($4.49 then, $2.38 on Nov 20, 2026). The figures date from before that move.10-Q

What comes next, and what happened

Its next results and latest dividend, and the filings that told of something: results, deals, people, debt. In plain words, each linked to the filing.

Next results

in 79 daysAround Feb 9, 2027 · for Q4 2026

last Nov 9, 2026next Feb 9, 2027

An estimate from when it has reported before, which has been regular. The company announces the date itself.

Its SEC filings

What it has filed lately, newest first, linked to the document itself.

Mar 12, 2026 latest annualNov 9, 2026 latest quarterly
  • Nov 13, 2026Other material events
    Form8-K
  • Nov 13, 2026Over-5% holder statement (passive) (amendment)
    FormSCHEDULE 13G/A
  • Nov 9, 2026Quarterly reportfor the period to Sep 30, 2026
    Form10-Q
  • Nov 9, 2026Results of operations
    Form8-K
  • Oct 15, 2026Results of operations, other material events
    Form8-K
  • Oct 2, 2026Other material events
    Form8-K
  • Sep 22, 2026Other material events
    Form8-K
  • Sep 8, 2026Other material events
    Form8-K
  • Aug 18, 2026Officer or director change, other material events
    Form8-K
  • Aug 14, 2026Over-5% holder statement (passive) (amendment)
    FormSCHEDULE 13G/A
  • Aug 13, 2026Over-5% holder statement (passive)
    FormSCHEDULE 13G
  • Aug 10, 2026Quarterly reportfor the period to Jun 30, 2026
    Form10-Q
  • Aug 10, 2026Results of operations
    Form8-K
  • Aug 3, 2026Regulation FD disclosure, other material events
    Form8-K
  • Jul 21, 2026Officer or director change
    Form8-K
  • Jul 13, 2026Regulation FD disclosure, other material events
    Form8-K
  • Jul 1, 2026Shares registered for employees
    FormS-8
  • Jun 29, 2026Regulation FD disclosure, other material events
    Form8-K
  • Jun 15, 2026Over-5% holder statement (passive)
    FormSCHEDULE 13G
  • Jun 8, 2026Regulation FD disclosure, other material events
    Form8-K
  • May 27, 2026Regulation FD disclosure, other material events
    Form8-K
  • May 15, 2026Over-5% holder statement (passive) (amendment)
    FormSCHEDULE 13G/A
  • May 15, 2026Regulation FD disclosure, other material events
    Form8-K
  • May 15, 2026Over-5% holder statement (passive)
    FormSCHEDULE 13G
  • May 11, 2026Results of operations
    Form8-K

From the company's record at the SEC (EDGAR). The topics of each 8-K are the item codes the company itself filed. Its whole record at the SEC, since Apr 9, 2008. Of its note and share prospectuses (424B, FWP), the newest 40 of 67.

The full analysis

What do Tonix Pharmaceuticals's filings show?

The filings are where every one of Tonix Pharmaceuticals's figures comes from. The full Ploutos AI analysis reads everything the company has filed and shows what stands behind it, with a source for every figure.

  • A fair value range built from the filings
  • Earnings quality, debt and red flags
  • Insider and institutional moves
  • The case for and the case against

All filings on EDGAR

Related pages

The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.

The figures come from the company's SEC filings and the share price, and describe what it has reported. They are not a score or a fair value.